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Clinical Implications and Hospital Outcome of Immune-Mediated
Myositis in Horses
L. Hunyadi, E.A. Sundman, P.H. Kass, D.C. Williams, and M. Aleman
Background: Immune-mediated myositis (IMM) is a cause of rhabdomyolysis, stiffness, and muscle atrophy predomi-
nantly affecting Quarter horses. Limited information is available with regard to outcome, prognostic indicators, and associa-
tions with concurrent diseases.
Hypothesis/Objectives: To report outcomes and associations between outcome and clinical and laboratory parameters,
and presence of concurrent illness.
Animals: Sixty-eight horses; 52 Quarter horses and related breeds and 16 other breeds.
Methods: Retrospective cohort study (1991–2014). Medical records of horses with histological diagnosis of IMM were
reviewed. Data recovery included signalment, laboratory variables, therapy, and outcome. Logistic regression was used to
quantify the association between potential prognostic factors and survival to discharge.
Results: Quarter horses were younger (mean < 4 years, range 3 months–21 years) than other breeds (mean < 10 years,
range 1–23 years). Pathogens causing concurrent or recent infection included S. equi equi, S. equi zooepidemicus, C. pseudotu-
berculosis, Anaplasma phagocytophilum, herpes virus-1, and influenza. The most common clinical signs consisted of rapidly
progressive diffuse symmetrical muscle atrophy (80%), stiff gait (74%), and fever (44%). All horses that received medical
therapy immediately upon admission survived to discharge (survival proportion = 87%). Leucocytosis was a common finding
(60%). Horses with concurrent fever and other illness had a poor prognosis for hospital discharge.
Conclusions and Clinical Importance: Horses with IMM can have a favorable outcome. Horses with concurrent fever and
another illness had decreased probability of survival to discharge.
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Immune-mediated myositis (IMM) occurs in humans,dogs, and horses.1–8 Immune-mediated myositis has
been predominantly described in Quarter horse and
related breeds and is characterized by rapid and diffuse
symmetrical muscle atrophy predominantly of gluteal
and epaxial muscles, lethargy, and stiffness.6 The pri-
mary laboratory findings include increase in creatine
kinase and aspartate aminotransferase activity on a
serum biochemistry panel.6 The main histological feature
of skeletal muscle biopsies is mononuclear cell infiltra-
tion of predominantly CD4+ T-lymphocytes and
myonecrosis.6,9 Immune-mediated myositis belongs to a
group of inflammatory myopathies.1 Myopathies can be
classified as noninflammatory and inflammatory
myopathies. Noninflammatory myopathies are a hetero-
geneous group of muscle diseases that lack inflammatory
cell infiltration as the predominant finding and might
present with or without myonecrosis when examined his-
tologically.10,11 Inflammatory myopathies are character-
ized by the presence of inflammatory cell infiltration as
the predominant histological finding and myonecrosis
and further classified on the basis of distinct clinico-
pathological features in humans and dogs.1,5,12 Inflam-
matory myopathies can result from infectious and
noninfectious causes.1 Examples of infectious causes in
dogs and horses include Acinetobacter calcoaceticus,
Clostridium spp., Corynebacterium pseudotuberculosis,
Salmonella infantum, Streptococcus equi subsp. equi, Sar-
cocystis spp., Toxoplasma gondii, and Neospora
caninum.3,13–19 Noninfectious inflammatory myopathies
causes include immune-mediated (dogs, horses) and
para- or preneoplastic syndromes (dogs).3,6,20
Noninfectious inflammatory myopathies are the lar-
gest group of potentially treatable myopathies in
humans and are classified based on clinicopathological
features into dermatomyositis, polymyositis, necrotizing
autoimmune myositis, inclusion body myositis, and
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overlap myositis.1 Inflammatory myopathies in dogs
include muscle masticatory myositis, extraocular myosi-
tis, dermatomyositis-like, polymyositis, and overlap
syndrome.3,8,21 Peer review reports of IMM in horses
are limited.6,7,9,22 Causes of IMM in horses have not
been fully elucidated, but temporal relationships have
been ascribed to autoimmunity developed to bacterial
or viral antigens.6,9,17,22 To our knowledge, there is
limited information published about clinical outcome,
physical examination findings at presentation, and
treatment of horses with IMM. Outcome, prognostic
indicators, and impact of treatments have not been
reported to the author’s knowledge. Therefore, the
objective of the study was to determine whether hospi-
tal outcome was associated with clinical or laboratory
findings, therapeutic modalities, or hospitalization time.
Specifically, associations of muscle enzyme elevations
and concurrent illness(es) with hospital outcome were
investigated.
Materials and Methods
Case Selection
Medical records from the William R. Pritchard Veterinary Med-
ical Teaching Hospital (VMTH) and the Neuromuscular Disease
Laboratory (NDL) at UC Davis were searched between the years
of 1991–2014 using the key words: inflammatory myopathy,
immune-mediated myositis, and myositis. Horses with records of
skeletal muscle biopsies were selected. The inclusion criteria con-
sisted of having a definitive diagnosis of IMM based on histologi-
cal findings on a muscle biopsy defined as the presence of
lymphocytic infiltration within myofibers, perimysial, epimysial,
and perivascular areas; and myonecrosis. Muscle specimens were
further analyzed to determine populations of B- and T-lympho-
cytes. Cases were excluded if pathogens such as bacteria or para-
sites were observed in the muscle specimen examined.
Data Acquisition
Information obtained from medical records included signal-
ment, onset of clinical signs, physical examination findings, CBC,
and chemistry panel performed at the time of admission, treat-
ment, duration of hospitalization, and outcome. Long-term fol-
low-up information was located within the medical record or
obtained by telephone communication with the owner, trainer, or
referring veterinarian.
Electromyography
Electromyography (EMG) was offered as part of the diagnostic
work-up for muscle disease in horses after the year of 2000. How-
ever, only six owners consented to the study. Electromyography
was performed using two machines upon availability (Viking IVDa,
VikingQuestb). A concentric needle electrode (26 gage by 50 mm
length, recording area of 0.07 mm2)c was used to perform the
EMG, and a subdermal needle electrode (30G by 20 mm)d served
as the ground. The muscles evaluated included the triceps brachii,
supraspinatus, infraspinatus, lumbar paraspinalis, gluteus medius,
quadriceps femoris, and semimembranosus muscles. To avoid fur-
ther damage to the muscles by the insertion of the EMG needle,
only one side of the horse was evaluated and three sites per mus-
cle were examined. Observed abnormalities were classified accord-
ing to a published grading system.23
Muscle Biopsy
Equine muscle biopsy specimens received at the NDL were snap
frozen in isopentane, precooled in liquid nitrogen, and stored at
80°C until further processing. Muscle specimens at the NDL
were routinely processed for histological and immunohistochemical
analysis and evaluated under light microscopy as previously
described.24 In brief, the following histochemical stains and reac-
tions were performed: hematoxylin and eosin, modified Gomori
trichrome, periodic acid Schiff, phosphorylase, esterase, staphylo-
coccal protein A-horseradish peroxidase, myosin ATPase at prein-
cubation pH of 9.8, 4.6, and 4.3, nicotinamide adenine
dinucleotide, succinate dehydrogenase, acid phosphatase, alkaline
phosphatase, and oil red O. Immunohistochemistry to determine
the type of inflammatory cells included clusters of differentiation
for B-lymphocytes (CD20+, CD79+), T-lymphocytes (CD3+,
CD4+, CD8+), and macrophages (CD11c+). All stains and reac-
tions previously mentioned were performed in samples collected
from 1999 to 2014 (n = 48 horses). Archived muscle biopsies from
two healthy horses were used as negative controls for immunophe-
notyping. For early recognition of suspected IMM, hematoxylin
and eosin were performed on muscle biopsies from 30 horses on
the day of biopsy.
Statistical Analysis
Initially, Fisher’s exact test was used to compare categorical
variables, and the exact Mann-Whitney test was used to compare
continuous variables between horses that either died or were euth-
anized because of a poor medical prognosis based on clinicians’
criteria (nonsurvivors) and horses discharged alive (survivors). For
those variables with a significant association (P < .05), exact logis-
tic regression was then used to quantify the magnitude of the asso-
ciation using odds ratios and 95% confidence intervals. Horses
that were euthanized for solely financial reasons were excluded
from prognosis analyses. All analyses were performed with stan-
dard software (Stata 1C/13.1e and LogXact-11f).
Results
Animals
Sixty-eight horses met the inclusion criteria. Fifty-two
(76%) of the 68 horses in this study were Quarter
horses or related breeds. Other breeds included Thor-
oughbreds (14%), Warmbloods (8%), and Arabians
(2%). The sex distribution of all horses consisted of 33
females, 27 geldings, and eight intact males. The sex dis-
tribution for Quarter horses and related breeds was 27
females, 19 geldings, and eight intact males. Mean age
at the time of initial examination at the VMTH was
5 years (range, 3 months to 23 years). The mean age of
Quarter horses and related breeds at initial examination
was <4 years old (range of 3 months–21 years), whereas
in other breeds, the average age was >10 years old
(range of 1–23 years). Median hospitalization time was
7 days (range, 3–26 days). Reported historical events
before the development of IMM included respiratory
infection within days to weeks (n = 19/68, 28%), and
vaccination within 3–4 weeks against influenza and her-
pes virus-1 (n = 13/68, 19%). Pathogens identified
through microbial culture or PCR or both causing con-
current or recent infection included S. equi equi (n = 5),
S. equi zooepidemicus (n = 4), C. pseudotuberculosis
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(n = 3), Anaplasma phagocytophilum (n = 3), equine her-
pes virus-1 (n = 3), and equine influenza virus (n = 1).
The most common clinical signs consisted of rapidly
progressive diffuse symmetrical muscle atrophy
(n =55/68, 80%) and stiff gait (n = 50/68, 74%). Other
common sign included fever in 44% of the horses
(n = 30/68; median 101.3°F [38.5°C], range 101–104°F
[38.3–40°C]; reference range 99–100.8°F [37.2–38.2°C]).
Recumbency was recorded in 8% of the horses
(n = 6/68).
Clinicopathologic data
White blood cell (WBC) counts were above the refer-
ence range in 60% of the horses (n = 41/68). Elevated
muscle enzyme activities (CK and AST) were identified
in 97% of the horses (n = 66/68) at the time of admis-
sion (Table 1). Other laboratory parameters are also
shown in Table 1. Troponin I was measured in two
Quarter horses with suspected cardiomyopathy based
on persistent tachycardia (60–80 bpm) during hospital-
ization and found increased (>0.17 and 0.35 ng/mL; ref-
erence range 0.01–0.07 ng/mL). Troponin I was within
reference value at the time of discharge.
Electromyography
Six of 68 horses had an electromyographic examina-
tion. These horses had nonspecific abnormalities con-
sisting of mild-to-moderate increased insertional
activity, fibrillation potentials (amplitude 50–200 lV,
duration 0.5–3 msec), and positive sharp waves (ampli-
tude 50 lV to 4 mV; duration <5 msec) in multiple
muscles examined.
Muscle Biopsy
As part of the inclusion criteria, all muscle specimens
examined had mononuclear cell infiltration that was
predominantly lymphocytic. Of 68 horses, 45 horses
had more than one muscle collected for histologic eval-
uation. Muscle biopsies were taken predominantly from
the gluteus medius muscles (n = 45/68 horses, 66%).
Other muscles included the semimembranosus (60%),
sacrocaudalis dorsalis lateralis (30%), triceps brachialis
(10%), and masseter (4%). Immunophenotyping
through clusters of differentiation were performed in
muscle biopsies from 18 horses. Lymphocytic cellular
infiltration was present around blood vessels in 66.7%
of muscle specimens examined, and within endomysial
and perimysial areas in 88.9% (Fig 1A). Lymphocytic
infiltration was predominantly CD4+ T-lymphocytes,
followed by CD8+ T-lymphocytes. CD20+ B-lympho-
cytes were observed in 39% of the cases (Fig 1B).
Macrophages, identified histologically and through acid
phosphatase enzymatic reaction and immunophenotyp-
ing (CD11c+), were observed in areas of myonecrosis
affecting all fiber types. These abnormalities had a mul-
tifocal coalescing to diffuse distribution throughout the
muscle specimen.
Table 1. Clinicopathologic data obtained at the time
of admission. N = number of horses with variable
above reference range/total number of horses evaluated
for such variable.
Variable Median (range)
Reference
Range
WBC count (cells/lL)
n = 41/68
13,697 (4,720–21,600) 5,000–11,600
Fibrinogen (mg/dL)
n = 24/47
500 (100–800) 100–300
SUN (mg/dL)
n = 14/47
27 (7–72) 12–27
Creatinine (mg/dL)
n = 8/47
1.5 (0.6–72) 0.9–2.0
Calcium (mg/dL)
n = 11/47
11.1 (8.2–14.3) 11–14
Potassium (mEq/L)
n = 0/47
3.8 (2.4–5.3) 3–5.5
AST (U/L) n = 66/68 12,270 (112–56,129) 165–495
CK (U/L) n = 66/68 101,071 (129–1,456,218) 120–287
A
B
Fig 1. (A) Lymphocytic and macrophages cellular infiltration
within endomysial (arrow) and perimysial (star) areas of gluteus
medius muscle shown on hematoxylin and eosin at 109,
bar = 200 lm. (B). Lymphocytic cellular infiltration consisting of
CD4+ T-lymphocytes (arrow) based on immunophenotyping of
gluteus medius muscle at 109, bar = 200 lm.
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Outcome and Follow-Up
Of the 68 horses included in the study, 59 (87%) sur-
vived to discharge, one (1%) died, eight (12%) were
euthanized. All horses that were treated medically (sup-
portive care with fluids administered IV, antimicrobials
for those with concurrent or suspected infection, with
or without corticosteroids) within 24 hours of admis-
sion to the VMTH survived to discharge (59/68 horses).
Twenty-eight horses were treated with corticosteroids,
and all survived to discharge. Corticosteroids used were
dexamethasone (0.05–0.1 mg/kg IV once or for a few
days with tapering dosages of 25% decreases in some
cases and then followed by oral prednisolone at 1 mg/
kg with tapering dosages as explained next under pred-
nisolone) and prednisolone (1 mg/kg PO q24h followed
by tapering dosages of 20–25% decreases over days to
weeks [2–6 weeks]).
Factors evaluated for their association with survival to
discharge are shown in Table 2. Concurrent illness alone
was not a significant prognostic indicator; however,
horses with concurrent fever and an additional illness had
a significantly decreased survival. Other specific factors
such as presentation during winter season, being a non-
Quarter horse, AST, and having a presumptive diagnosis
of immune-mediated myositis upon hospital admission
were also significantly associated with outcome.
Long-term follow-up information (6 months after
hospital discharge) was available for 59 horses. Nine-
teen (32%) horses, all of Quarter horse breed (n = 19/
52; 37%), had a recurrence of IMM within 6 months of
hospital discharge. Of these, 17 (90%) survived
3 months past the second IMM episode, whereas two
(10%) did not survive the second episode. Fifty-seven
(84%) horses were reported healthy by 6 months after
hospital discharge. All surviving horses that had muscle
atrophy during hospitalization regained their muscle
mass within 3–6 months. Both horses that did not sur-
vive the second episode of IMM were in chronic renal
failure that resulted from an acute insult that developed
during the first episode of IMM.
Discussion
This report demonstrates that horses with immune-
mediated myositis have a high survival rate. Concurrent
illness together with fever was significantly associated
with nonsurvival, although concurrent illness or fever
alone were not. Acute renal failure could have been a
result of the combination of pigment nephropathy due to
the deposition of myoglobin in conjunction to nons-
teroidal anti-inflammatory drug administration and
dehydration before referral. Rhabdomyolysis and acute
renal failure occur in humans.25 Although there was no
specific concurrent illness or history associated with the
development of IMM, clinical signs observed in these
horses were similar to those described in a previous
study.6 Clinical signs commonly observed in both studies
were a stiff gait, lethargy, and muscle atrophy most nota-
bly over the epaxial, gluteal, and neck/shoulder muscles
developing within the first few days of hospitalization.
Although medical treatment was used in all horses
that survived to discharge, it was not the goal of this
study to evaluate the relative efficacy of treatments due
to the retrospective study design and the potential for
confounding by clinical indication. It should be suffi-
cient to note that prompt therapy was associated with a
favorable prognosis.
In this study, all horses evaluated through an EMG
study had nonspecific alterations consisting of pro-
longed insertional activity, fibrillation potentials, and
positive sharp waves. These abnormalities occur in
humans and dogs with inflammatory myopathies.26–28
Fibrillation potentials and positive sharp waves arise
from spontaneously firing hypersensitive myofibers as
the result of destabilization of the sarcolemmal
membrane.23 Therefore, these abnormal findings are not
exclusive of inflammatory myopathies and can also be
observed in neuropathies and other myopathies.23 Fur-
ther, due to the low number of cases examined through
an EMG in this study, there is a potential for bias.
Identifying definitive causes of the development of
IMM in these horses was not a goal of this study, nor
could it be due to the study’s retrospective cohort
design. However, a possible association between previ-
ous respiratory infection and vaccination was suspected
in 38% of the cases. Quarter horses and related breeds
appeared to be over-represented (76% of cases); how-
ever, this assumption cannot be definitively made
because the distribution of breeds in the source popula-
tion of cases is unknown. Further, Quarter horses and
related breeds were younger than other breeds (mean
age < 4 years versus > 10 years, respectively). The
pathophysiology for the development of IMM in
humans has been presumed to be due to the lack of
self-tolerance to antigens expressed by muscle cells, acti-
vation of T-lymphocytes by shared epitopes with infec-
tious agents causing antigenic mimicry, microbial
superantigens, and high concentration of local
cytokines.1,2,29 The exact mechanism of disease in the
horse is unknown but possibly involves a similar mech-
anism of loss of self-tolerance to antigens expressed by
muscle cells, resulting in the development of autoimmu-
nity against its own muscle cells. Based on the results of
the present study, the authors speculate that this sus-
pected autoimmunity can occur within days to weeks
(up to 4 weeks) after the exposure to pathogens (bacte-
rial, viral) and other antigens (presumably peptides con-
tained in vaccines) in some cases. A possible association
between autoimmunity and breed predisposition has
been considered.6 Pathogens associated with disease in
the present study included S. equi equi, S. equi zooepi-
demicus, C. pseudotuberculosis, Anaplasma phagocy-
tophilum, equine herpes virus-1, and equine influenza
virus. Vaccines suspected to be associated with IMM
included influenza and herpes virus-1. Rhabdomyolysis
associated with influenza virus natural and experimental
infection occur in humans and mice, respectively.25,30
Based on immunophenotyping, predominant CD4+
followed by CD8+ T-lymphocytes, a cellular immune
response was responsible for the observed myonecrosis.
This finding was similar to that described in previous
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studies in horses.6,9 In our study, CD20+ B-lymphocytes
were not a major component of this suspected autoim-
munity. Further, staphylococcal protein A-horseradish
peroxidase for the detection of IgG antibodies in the
muscle cell membrane did not reveal antibody staining.
Myonecrosis resulted in the elevation of muscle enzyme
activities (median: AST 12,270 U/L, CK 101,071 U/L).
Lewis et al.6 described IMM in horses as having
increased muscle enzyme activity with persistently high
concentrations of AST (>1,000 U/L) and CK (>10,000
U/L) and ascribed it to chronic and active myofiber
destruction. Despite marked increases in muscle enzyme
activities, AST and CK were not a useful prognostic
indicator for outcome in our study. Cardiomyopathy
was presumed to be associated with IMM, but this was
not confirmed histologically because the two horses
fully recovered. Many of the horses (78%) had a con-
current infection within various body systems, including
respiratory and gastrointestinal systems. Importantly,
the presence of a suspected bacterial, viral, or parasitic
infection was not associated with decreased survival.
Additionally, horses with infections were treated with
corticosteroids in this study population. Long-term
prognosis for horses with IMM based on a 6-month fol-
low-up information is favorable. However, one-third of
horses in this study had a recurrent episode within
6 months of the initial presentation. Prognosis from the
second IMM episode was also favorable. A causative
agent, disease, or illness could not be attributed to the
IMM recurrence. Horses that did not survive the second
IMM episode had evidence of chronic renal failure that
was unresponsive to IV fluid diuresis. These horses had
acute renal failure during their initial IMM and subse-
quent renal damage during their second episode. The
azotemia associated with these nonsurvivors was attrib-
uted to myoglobin nephrosis (histologically confirmed)
secondary to myonecrosis associated with IMM.
In conclusion, IMM is a cause of apparent muscle
pain, stiffness, and rapid muscle atrophy that occurs
within days due to marked rhabdomyolysis as evidenced
by elevated muscle enzyme activities. Horses with
IMM might present with fever, leukocytosis, and
Table 2. Factors hypothesized to be associated with survival to discharge in 68 horses with IMM.
Variable Horses (n)
Fisher’s exact
P-value Odds ratio
95% Confidence
interval
Logistic regression
P-value
History
Winter season (vs all others) 68 .014 8.19 1.23–55.31 .028
Year 68 .119
Housing (stall vs pasture) 30 1.000
Vaccination history (positive) 68 1.000
Signalment
Age (1 year) 68 .311
Breed (Quarter horse) 37 1.00 – –
Breed (nonQuarter horse) 16 .008 15.35 1.50–794.28 .011
Breed (Quarter horse-related) 15 8.55 0.62–485.10 .1
Sex (female) 33
Sex (gelding) 27 1.000
Sex (intact male) 8
Weight (9100 kg) 21 .153
Physical examination
Temperature (1°F) 67 .564
Fever present 68 .253
Concurrent illness present 68 .189
Fever and concurrent illness 68 .033 8.07 0.98–379.19 .041
Edema present 40 .233
Vasculitis present 36 .691
Lameness present 68 1.000
Lameness grade (1 unit increase) 67 .431
Neurologic deficits present 68 .340
Neurologic grade (1 unit increase) 67 .634
Laboratory
WBC (91,000 cells/lL) 67 .944
Fibrinogen (9100 mg/dL) 67 .867
AST (91,000 U/L) 67 .013 0.85 0.68–0.98 .01
CK (910,000 U/L) 67 .176
Creatinine (mg/dL) 67 .118
SUN (910 mg/dL) 67 .831
Calcium (mg/dL) 67 .278
Potassium (mEq/L) 66 .753
Muscle biopsy
Early presumptive diagnosis on admission 66 .003 10.12 1.79–74.35 .005
Treatment
Steroid therapy 68 .151
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hyperfibrinogemia. Monitoring of renal variables is
important because renal insult resulting in failure is a
potential complication. Although IMM can occur can
in horses of various breeds, Quarter horses and related
breeds seem to be predisposed.6,9 Therefore, a familial
or genetic bases for the development of disease must be
considered in this breed. Electromyographic alterations
are observed in affected horses. Immune-mediated
myositis can have a favorable outcome if clinical signs
are recognized early and treatment with corticosteroids
is initiated promptly along with supportive care and
treatment of any concurrent illness including antimicro-
bial therapy for those horses with concurrent bacterial
infection. However, horses that presented with concur-
rent fever and an additional illness had diminished sur-
vival. Muscle mass recovery might take 3–6 months
after the insult, and return to work is possible. Quarter
horses might suffer from recurrent episodes of IMM.
Footnotes
a Viking IVD, Nicolet Biomedical Inc., Madison, WI
b VikingQuest, Nicolet Biomedical Inc., Madison, WI
c Disposable concentric needle electrode, VIASYS Healthcare,
Madison, WI
d Subdermal Grass electrode, Astro-Med Inc., West Warwick, RI
e Stat 1C/13.1, StataCorp. LP, College Station, TX
f LogXact-11, Cytel Software Corporation, Cambridge, MA
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